Skip to content

Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients

Contribution of a Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03520855
Acronym
eDIVE
Enrollment
78
Registered
2018-05-11
Start date
2019-04-03
Completion date
2024-11-27
Last updated
2026-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Type 1 Diabetes, Paediatrics patients

Brief summary

The aim of this study is to evaluate the contribution of a serious game in the reinforcement of knowledge acquired during therapeutic education of type 1 diabetes paediatric patients. This evaluation will take place within 3 months of the diagnosis.

Detailed description

Type 1 diabetes gather multiple metabolic pathologies secondary to a deficiency in insulin secretion or insulin action, characterized by chronic hyperglycaemia. Diagnosis is based on fasting glycaemia above 1.26 g/l or above 2 g/l any time of the day. Currently, it is recommend initial therapeutic education additionally to insulin therapy, in the type 1 diabetes care. Initial therapeutic education's role is to develop 3 specific skills : self-care skills, safety skills and adaptation skills. This approach gives to the patient the abilities to monitor himself, to handle emergency situations and to modify his lifestyle to treat his disease correctly. In the serious game, the patient will directly evolve in a virtual environment, with places reflecting his real life such as paediatric diabetology centre, hospital, home, school. He will have to complete quests with his own virtual avatar, that reflect situations his disease can confront him to. Each quest ends with a questionnaire. The principal objective of this research is to evaluation the contribution of a serious game (DIVE) in the reinforcement of knowledge acquired during therapeutic education of type 1 diabetes paediatric patients. This research is designed in two arms, gathering 100 patients, each arm has 50 patients. Both arms benefit initial therapeutic education, except the experimental group which is added a serious game . To measure the impact of the serious game,investigators will compare HbA1c dosage between groups (with HPLC technique), 3 months after diagnosis; but also the number of hypo or hyperglycaemia in the month before M3 final consultation. They will also evaluate self-care skills and safety skills with role-plays at the end of hospitalisation and 3 months later. Technical gestures will also be evaluated by referent nurses. Evaluation of the patient's well-being will take place with two types of questionnaire, WHO-Five and DOQLY during M3 final consultation. This research will bring essential information on the development of video games in other paediatric chronic diseases, as a first step in the development of the use of video games in therapeutic care of type 1 diabetes.

Interventions

OTHERSerious game

DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.

BEHAVIORALETP

Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book. Health education sessions will also be taught by nurses.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Child aged from 10 to 17 and 8 months * Child with a type 1 diabetes (inclusion within 96 hours following the diagnosis, except for patients admitted to intensive care for whom an additional 48-hour period is accepted for their inclusion). Diagnosis will be confirmed based on one of the classic diagnostic criteria: venous glycaemia above 2 g / l, presence of polyuropolydipsic syndrome, presence of weight loss, presence of ketonuria (equivalent to at least one cross in urine or\> 0.5mmol / l in blood) * Child with internet access and with a computer or a tablet or a mobile phone in at least one of the two parents or legal representative(s) * Informed consent signed by parents or legal representative(s) (only one parent possible) * Beneficiary of a social security system

Exclusion criteria

* No internet access or no computer or no tablet or no mobile phone at home available * No French language proficiency of the infant or legal representative(s) * Inability to understand the game's instructions * Inability to understand or fill the consent

Design outcomes

Primary

MeasureTime frameDescription
Diapason questionnaire (Aide aux Jeunes Diabètes)3 months50 questions (disease, treatment, food,…)

Secondary

MeasureTime frameDescription
HbA1c dosage3 monthsGlycemia follow-up with a self-monitoring book in each arm
Number of hypo or hyperglycaemia3 monthsStatement of the number of hypo or hyperglycaemia within the months preceding the consultation
Evaluation of self-care skills3 monthsEvaluation of self-care skills with role-plays and assessment of feelings of competence from their DT1 (scorecard, Barrow chart )
Evaluation of well-being with WHOFIVE3 monthsEvaluation of patient's well-being with auto-questionnaires
Evaluation of well-being with DQOLY3 monthsEvaluation of patient's well-being with auto-questionnaires

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJacques BELTRAND, MD, PhD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026